This study looks at the impact of a medication called naltrexone/bupropion (brand names: Contrave or Mysimba) on heart health. It's a special type of study called double-blinded, which means neither the doctors nor the patients know who is getting the real medicine and who is getting a placebo (a fake pill). The study checks if people taking the medicine have more heart problems than those taking the placebo. Participants will also be guided on how to lose weight through diet and exercise.

Eligibility: Adults 18 or older with a Body Mass Index (BMI) of 27 or higher and at risk of heart problems can join. People who take other weight loss medicines, have recent heart attacks, or have certain health issues cannot participate.

• The study involves regular check-ins and using a smartphone app.
• Participants must stop other weight loss treatments before joining.
• Potential risks and benefits will be explained before participation.